Peptide Monographs

BPC-157 and KPV side by side

BPC-157 and KPV are both indexed under Tissue repair peptides. Every cell below carries the record it came from, and an axis with no retrieved value reads Unknown rather than being filled by inference.

Summary

Both are short peptides whose retrieved literature is concentrated on the gut. KPV is the C-terminal tripeptide of alpha-MSH, and the cited 2008 Gastroenterology and Inflammatory Bowel Diseases papers report anti-inflammatory activity in intestinal models; BPC-157 is a gastric pentadecapeptide first reported in the cited 1994 record.

[1, 2, 3, 4]

Side by side

Curated comparison axes for BPC-157 and KPV
AxisBPC-157KPV
Reported mechanismThe retrieved literature frames the mechanism in terms of a relation to the nitric oxide system, and reports effects on growth hormone receptor expression in tendon fibroblasts. No single receptor target is established in the retrieved record set.[4, 9]The C-terminal tripeptide of alpha-MSH; the retrieved records report anti-inflammatory activity and PepT1-mediated uptake in intestinal epithelium.[1, 2]
Molecular formulaC62H98N16O22[5]C16H30N4O4[11]
Molecular weight1419.5 g/mol[5]342.43 g/mol[11]
FDA application registerA query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[6]A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[12]

Where the two literatures diverge

Origin and mechanism diverge. KPV derives from a melanocortin hormone and the cited records report PepT1-mediated uptake into intestinal epithelium; BPC-157 is framed in the cited 2014 Current Pharmaceutical Design paper against the nitric oxide system. The two differ in length by twelve residues and in molecular weight by roughly a factor of four on the retrieved PubChem records. Neither returned an FDA application record.

[1, 2, 3, 4]

Where this page sits

Full pages: BPC-157 and KPV.

Shared class: Tissue repair peptides.

Other pairs in the same class

All side-by-side pages: index.

Sources

  1. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology (2008). pmid:18061177
  2. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory bowel diseases (2008). pmid:18092346
  3. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. Life Sci (1994). pmid:7904712
  4. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des (2014). pmid:23755725
  5. PubChem Compound Summary for CID 9941957, Bpc-157. PubChem, National Library of Medicine (2026). pubchem:9941957
  6. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:bpc-157
  7. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol (1997). pmid:9298922
  8. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985) (2011). pmid:21030672
  9. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules (2014). pmid:25415472
  10. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol (2007). pmid:17628536
  11. PubChem Compound Summary for CID 125672, Msh (11-13). PubChem, National Library of Medicine (2026). pubchem:125672
  12. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:kpv
  13. Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit. Peptides (1984). pmid:6333677
  14. Anti-inflammatory activity of alpha-MSH(11-13) analogs: influences of alteration in stereochemistry. Peptides (1991). pmid:1788140
  15. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. The Journal of pharmacology and experimental therapeutics (2003). pmid:12750433
  16. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. The Journal of investigative dermatology (2004). pmid:15102092
  17. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cellular and molecular gastroenterology and hepatology (2016). pmid:27458604
  18. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular therapy : the journal of the American Society of Gene Therapy (2017). pmid:28143741
  19. <i>In situ</i> mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis. Biomaterials science (2021). pmid:34846053
  20. A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Acta biomaterialia (2022). pmid:35245681
  21. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Experimental eye research (2006). pmid:16965771

On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.

Related resources